High α-Fetoprotein Level in HCV- Related Nodular Liver Cell Dysplasia

Ng Fook-Hong; Chow Kai-Chiu; Cheng Chi-Sing; Kng Carolyn; Ng Wing-Fung; Wong Benjamin Chun-Yu
August 1999
American Journal of Gastroenterology;Aug1999, Vol. 94 Issue 8, p2296
Academic Journal
The diagnosis of hepatocellular carcinoma is generally made in patients with a mass lesion in the cirrhotic liver if the α-fetoprotein level is >1,000 ng/L. Other causes of elevation of α-fetoprotein to this extreme degree include nonseminomatous germ cell tumor and hepatic metastasis. However, it is extremely rare for benign hepatic lesions to cause α-fetoprotein of > 1,000 ng/ml. We report a Chinese patient with spontaneous normalization of α-fetoprotein with an initial value > 10,000 ng/ml due to nodular dysplasia complicating hepatitis C-related liver cirrhosis. The α-fetoprotein was secreted from the dysplastic liver cells.


Related Articles

  • Spontaneous regression of hepatocellular carcinoma. Kondo, Shunsuke; Okusaka, Takuji; Ueno, Hideki; Ikeda, Masafumi; Morizane, Chigusa // International Journal of Clinical Oncology;Oct2006, Vol. 11 Issue 5, p407 

    We report four patients with hepatocellular carcinoma (all men, with liver cirrhosis and hepatitis C virus infections) who showed spontaneous regression of the tumor. When the spontaneous regression occurred all of the patients were over age 67 years. They showed a rapid increase of serum...

  • Clinical Utility of AFP-L3% Measurement in North American Patients with HCV-Related Cirrhosis. Sterling, Richard K.; Jeffers, Lennox; Gordon, Fredric; Sherman, Morris; Venook, Alan P.; Reddy, K. Rajender; Satomura, Shinji; Schwartz, Myron E. // American Journal of Gastroenterology;Oct2007, Vol. 102 Issue 10, p2196 

    BACKGROUND AND AIMS: Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein (AFP-L3%) has been reported to be useful in the early detection of hepatocellular carcinoma (HCC) in Japan. The aim of this prospective study was to compare the clinical utility of AFP-L3% with that of total...

  • Percutaneous Ethanol Injection Therapy in the Treatment of Hepatocarcinoma - Results Obtained from a Series of 88 Cases. Danila, Mirela; Sporea, loan; Sirli, Roxana; Popescu, Alma // Journal of Gastrointestinal & Liver Diseases;Sep2009, Vol. 18 Issue 3, p317 

    Aim: To assess the efficacy of Percutaneous Ethanol Injection Therapy (PEIT) for the treatment of hepatocarcinoma in a series of Romanian patients, and to compare it with previous studies. Material and method: We retrospectively evaluated 88 patients with liver cirrhosis (LC) and hepatocellular...

  • Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. Tateyama, Masakuni; Yatsuhashi, Hiroshi; Taura, Naota; Motoyoshi, Yasuhide; Nagaoka, Shinya; Yanagi, Kenji; Abiru, Seigo; Yano, Koji; Komori, Atsumasa; Migita, Kiyoshi; Nakamura, Minoru; Nagahama, Hiroyasu; Sasaki, Yutaka; Miyakawa, Yuzo; Ishibashi, Hiromi // Journal of Gastroenterology;Jan2011, Vol. 46 Issue 1, p92 

    Background: Noninvasive risk factors are required for predicting the development of hepatocellular carcinoma (HCC) not only in patients with cirrhosis but also in those with chronic hepatitis who are infected with hepatitis C virus (HCV). Methods: A total of 707 patients with chronic HCV...

  • Immunohistochemical Detection of HCV in Cirrhosis, Dysplastic Nodules, and Hepatocellular Carcinomas with Parallel-Tissue Quantitative RT-PCR. Rullier, Anne; Trimoulet, Pascale; Urbaniak, Rosa; Winnock, Maria; Zauli, Daniela; Ballardini, Giorgio; Rosenbaum, Jean; Balabaud, Charles; Bioulac-Sage, Paulette; Bail, Brigitte Le // Modern Pathology;May2001, Vol. 14 Issue 5, p496 

    Hepatitis C virus is a major risk factor for hepatocarcinogenesis in humans. In situ detection of the virus in early sequential lesions of hepatocarcinogenesis could provide information about the role of the virus in the transformation and promotion process. Parallel in situ detection of HCV...

  • Efficacy and safety of 6-month iron reduction therapy in patients with hepatitis C virus-related cirrhosis: a pilot study. Tanaka, Naoki; Horiuchi, Akira; Yamaura, Takahiro; Komatsu, Michiharu; Tanaka, Eiji; Kiyosawa, Kendo // Journal of Gastroenterology;Jan2007, Vol. 42 Issue 1, p49 

    Iron reduction therapy (IRT) has been recognized as beneficial for chronic hepatitis C patients. However, its efficacy for hepatitis C virus-related liver cirrhosis (LC-C) has not been elucidated. We evaluated the efficacy and safety of IRT for LC-C patients. Twenty-two LC-C patients were...

  • Ultrasound guided Fine needle biopsy of early hepatocellular carcinoma complicating liver cirrhosis: a multicentre study. Caturelli, E.; Solmi, L.; Anti, M.; Fusilli, S.; Roselli, P.; Andriulli, A.; Fomari, F.; del Vecchio Blanco, C.; de Sio, I. // Gut;Sep2004, Vol. 53 Issue 9, p1356 

    Background: Because hepatic cirrhosis is a major risk factor for hepatocellular carcinoma, recent guidelines by the European Association for the Study of the Liver (EASL) on clinical management of hepatocellular carcinoma recommend periodic ultrasound surveillance of cirrhotic patients with...

  • Ultrasound Follow-Up of Patients at Risk for Hepatocellular Carcinoma: Results of a Prospective Study on 360 Cases. Solmi, Luigi; Manila Primerano, Anna Maria; Gandolfi, Lionello // American Journal of Gastroenterology;Jun1996, Vol. 91 Issue 6, p1189 

    Objectives: We performed a prospective study with ultrasound (US) follow-up on a population at risk for hepatocellular carcinoma (HCC) to evaluate the possibilities of diagnosis of HCC at an early stage. Methods: We studied 360 patients; 254 of those patients had cirrhosis of the liver (of which...

  • Boronate Affinity Chromatography of γ-Glutamyltransferase in Patients with Hepatocellular Carcinoma. Yamamoto, Tetsuo; Amuro, Yoshiki; Matsuda, Yoshinobu; Nakaoka, Hiroko; Shimomura, Souji; Hada, Toshikazu; higashino, Kazuya // American Journal of Gastroenterology;Apr1991, Vol. 86 Issue 4, p495 

    We analyzed the serum γ-glutamyltransferase (γ-GT) by boronate affinity chromatography to ascertain the presence or absence of any changes in the binding properties of γ-GT toward boronate gels in patients with hepatocellular carcinoma and liver cirrhosis, and in normal controls. The...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics